PARP Inhibitor + Avastin Delays Cancer Progression When Used as Initial Treatment for Ovarian Cancer

Maintenance therapy with the PARP inhibitor Lynparza olaparib added to Avastin bevacizumab resulted in a significant and clinically meaningful delay in cancer progression in patients with advanced stage III-IV ovarian cancer 160according to the results of [...]

Lynparza-Avastin Maintenance Delays Progression of Ovarian Cancer

Results from the phase III PAOLA-1 clinical trial in women with advanced ovarian cancer evaluating maintenance therapy with Lynparza olaparib plus Avastin bevacizumab compared to Avastin alone in women with or without BRCA gene mutations have been release [...]